Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Reichardt

Showing results (91-100 of 193) with videos related to

Pageof 20
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II studyPeter C Thuss-Patience, Albrecht Kretzschmar, Michael Repp, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2017
Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG)Bernd Kasper, Viktor Gruenwald, Peter Reichardt, et al.
British Journal of Cancer|March 24, 2017
SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumourOlli-Pekka Pulkka, Bengt Nilsson, Maarit Sarlomo-Rikala, et al.
ESC Heart Failure|April 20, 2018
Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathyFabian Muehlberg, Stephanie Funk, Leonora Zange, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2009
Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS)Alessandro Gronchi, Ian Judson, Toshirou Nishida, et al.
BMC Cancer|August 11, 2016
Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patientsMarkus K Schuler, Sebastian Gerdes, Antje West, et al.
Sarcoma|May 3, 2012
Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) StudyPeter Reichardt, Michael Leahy, Xavier Garcia Del Muro, et al.
Plos One|March 25, 2021
Utilization of in- and outpatient hospital care in Germany during the Covid-19 pandemic insights from the German-wide Helios hospital networkAndreas Bollmann, Sven Hohenstein, Vincent Pellissier, et al.
Journal of Cellular and Molecular Medicine|January 14, 2022
Fibrinogen-like protein 2 in gastrointestinal stromal tumourOlli-Pekka Pulkka, Leevi Viisanen, Olli Tynninen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 5, 2014
αPIX RhoGEF supports positive selection by restraining migration and promoting arrest of thymocytesMark Korthals, Kerstin Schilling, Peter Reichardt, et al.
Pageof 20

Showing results (91-100 of 193) with videos related to

Sort By:
Pageof 20
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II studyPeter C Thuss-Patience, Albrecht Kretzschmar, Michael Repp, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2017
Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG)Bernd Kasper, Viktor Gruenwald, Peter Reichardt, et al.
British Journal of Cancer|March 24, 2017
SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumourOlli-Pekka Pulkka, Bengt Nilsson, Maarit Sarlomo-Rikala, et al.
ESC Heart Failure|April 20, 2018
Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathyFabian Muehlberg, Stephanie Funk, Leonora Zange, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2009
Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS)Alessandro Gronchi, Ian Judson, Toshirou Nishida, et al.
BMC Cancer|August 11, 2016
Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patientsMarkus K Schuler, Sebastian Gerdes, Antje West, et al.
Sarcoma|May 3, 2012
Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) StudyPeter Reichardt, Michael Leahy, Xavier Garcia Del Muro, et al.
Plos One|March 25, 2021
Utilization of in- and outpatient hospital care in Germany during the Covid-19 pandemic insights from the German-wide Helios hospital networkAndreas Bollmann, Sven Hohenstein, Vincent Pellissier, et al.
Journal of Cellular and Molecular Medicine|January 14, 2022
Fibrinogen-like protein 2 in gastrointestinal stromal tumourOlli-Pekka Pulkka, Leevi Viisanen, Olli Tynninen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 5, 2014
αPIX RhoGEF supports positive selection by restraining migration and promoting arrest of thymocytesMark Korthals, Kerstin Schilling, Peter Reichardt, et al.
Pageof 20